In summary, FAVO weakened the proliferation, migration, and invasion of human gastric cancer SGC-7901 cells, inhibited vessel formation of zebrafish, impaired the tubule formation ability of HUVECs, suppressed tumor growth in vivo, increased the serum levels of IL-2 and IFN-γ in tumor-bearing nude mice, and inhibited HIF-2α-VEGF signaling. The gene discussed is EPAS1; the disease is neoplasm.